In a randomized controlled trial of an anti-IL-1β monoclonal antibody (CANTOS study), originally designed as a secondary prevention trial to reduce cardiovascular events, serum CRP and IL-6 were found to be associated with lung cancer incidence [48] and with time to cancer diagnosis [49]. This evidence concerns the gene CRP and lung carcinoma.